Merck & Co. et al., 2011-03-22: Joint Merck/sanofi-aventis release confirming that the 2010 plan to merge Merial with Intervet/Schering-Plough was terminated, so Merck kept its animal-health business separate.
Merck (NYSE: MRK) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet/Schering-Plough, Merck's animal health unit.
Merck & Co. et al., 2011-03-22: Joint Merck/sanofi-aventis release confirming that the 2010 plan to merge Merial with Intervet/Schering-Plough was terminated, so Merck kept its animal-health business separate. Company press release (joint). The original combination agreement was announced 2010-03-09 and filed with the SEC as Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/310158/000095012310023615/y83225exv99w1.htm); this 2011 release records the termination. No study. Context: this kept the Panacur/Safe-Guard fenbendazole franchise with Merck. Study type: news.
